Clinical Trial Update: Carboplatin or Olaparib for BRcA Deficient Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating carboplatin or olaparib in BRCA-deficient metastatic castration-resistant prostate cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Olaparib (Olaparib)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 | Phase 2 | Status: RECRUITING